Application of superior laryngeal nerve block combined with remimazolam in bronchoscopy

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400090103

Enrollment

Unknown

Registered

2024-09-24

Start date

2024-10-01

Completion date

Unknown

Last updated

2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia

Interventions

Group N:Ultrasound-guided anterior approach superior laryngeal nerve block combined with remimazolam sedation

Group C:Lidocaine spray combined with remimazolam sedation

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1) Patients classified as ASA I-II require bronchoscopy, including but not limited to suspected lung cancer, bronchial stenosis, or suspected hemoptysis. 2) No known allergies to anesthetic agents. 3) No severe coagulation disorders or bleeding tendencies.

Exclusion criteria

Exclusion criteria: 1) Allergy to local anesthetics, severe cardiovascular disease, respiratory failure, or impaired consciousness 2) Abnormal anatomical structure of the neck or larynx that may interfere with localization 3) Pregnant or lactating women 4) Patients who are participating in other clinical trials 5) Those who are considered unsuitable for clinical trials by the investigators for other reasons

Design outcomes

Primary

Measure	Time frame
Mean Arterial Pressure(MAP);Heart Rate(HR);	—

Countries

China

Contacts

Public ContactJinwen Ma

Anyang Tumor Hospital

guodongdemail@163.com+86 188 3726 2561

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026